Page 5 - Frier Levitt News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Many have celebrated the historic strides in healthcare made in the recent Inflation Reduction Act that passed the House on Friday, praising the eventual start of Medicare negotiating drug prices. But not all believe it will make a huge difference on the drug industry in general, particularly since it left out people who are covered by private insurance, and left pharmacy benefit managers, who negotiate drug prices, off the hook.  The Inflation Reduction Act included a provision that Medicare would begin negotiating drug prices in 2026, a top desire by some lawmakers who for years have tried to have more government intervention in the drug pricing industry. The Congressional Budget Office estimated that the provisions would save the Center for Medicare & Medicaid services nearly $102 billion by 2031. Meanwhile, skeptics say that more government intervention could lead to less innovation and affect the relationship between drug companies and investors.  Steven Bennet, a partner i

Steven bennetFrier levittCongressional budget officeInflation reduction actFederal trade commissionWeight lossMedical devicesHealthcare innovationMedcity newsMedcity newsSan franciscoLife sciencesRock healthStartup adviceStartup fundingPatient monitoring system